Omeros Corporation Stock News

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced the closing of the asset sale and licensing transaction between Omeros and Novo Nordisk for the candidate drug zaltenibart (formerly OMS906). Zaltenibart is a first-in-class, late-stage clinical humanized monoclonal antibody targeting MASP-3 – the most upstream and key activator of the alternative pathway of the complem...

Omeros Corporation ( OMER ) Q3 2025 Earnings Call November 13, 2025 4:30 PM EST Company Participants Gregory Demopulos - Co-Founder, Chairman, CEO & President David Borges - VP of Finance, Chief Accounting Officer & Treasurer Nadia Dac - VP & Chief Commercial Officer Conference Call Participants Jennifer Williams Brandon Folkes - H.C. Wainwright & Co, LLC, Research Division Stephen Brozak - WBB...

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced recent highlights and developments as well as financial results for the third quarter ended September 30, 2025, which include: Net loss for the third quarter of 2025 was $30.9 million, or $0.47 per share, compared to a net loss of $32.2 million, or $0.56 per share for the third quarter of 2024. For the nine months ended...

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its financial results for the quarter ended September 30, 2025, on Thursday, November 13, 2025, after the market closes. Omeros management will host a conference call and webcast that same day at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss the financial results as well as rece...

Momentum investors rely on a combination of astute analysis and timing to maximize gains. While this approach can carry a fair degree of risk, the allure of identifying a fast-growing stock and joining a rally that has room to continue is powerful.

Omeros Corporation maintaining a Strong Buy rating after securing a $2.1 billion partnership with Novo Nordisk for MASP-3 inhibitor zaltenibart. OMER's zaltenibart targets Paroxysmal Nocturnal Hemoglobinuria with a differentiated mechanism, offering potential safety and dosing advantages over existing complement inhibitors. Recent phase 2 data showed significant improvements in hemoglobin and L...

Omeros Corporation's stock surged over 150% after licensing zaltenibart to Novo Nordisk for $340M upfront, plus milestones and royalties. The deal provides OMER with critical funding, alleviating bankruptcy concerns and supporting operations through 2027 as it pursues FDA approval for narsoplimab. Zaltenibart's unique MASP-3 inhibition offers advantages in PNH, attracting NVO, which seeks to di...

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced the publication of a peer-reviewed manuscript in Blood Advances, a journal of the American Society of Hematology, detailing survival outcomes in adult patients with life-threatening transplant-associated thrombotic microangiopathy (TA-TMA) treated with narsoplimab across both the pivotal clinical trial and the global ex...